Edinburgh, UK, 5th December 2018 / Synpromics is pleased to hear that its partner, uniQure (NASDAQ:QURE), has announced the incorporation of its promoter, developed by Synpromics, in a new preclinical research target. This follows recent positive data, presented at the ESGCT world congress, demonstrating that this highly selective liver promoter is at least eight times more potent than the current industry standard.
A new video from Synpromics’ investor, Calculus Capital, discusses why they invest and how this has aided development of our synthetic promoter technology.
Sarah Haecker Meeks and David Venables enjoyed the sun in San Diego earlier this month for the annual ARM Cell & Gene Meeting on the Mesa. Nearly 1000 senior executives, key decision makers and scientists congregated to share recent developments and advance cutting edge research in cell and gene therapy. This year’s conference saw a noticeable uptick in interest in next generation gene medicines and strategies to improve current products in development.
Edinburgh, 18th October, 2018 / Synpromics is pleased to announce positive data presented today by a key partner, uniQure (NASDAQ:QURE), at the European Society of Gene and Cell Therapy conference in Lausanne, Switzerland. The study used uniQure’s next-generation liver-directed gene therapy system that incorporates a short, highly-selective and powerful liver promoter that was developed by Synpromics.